'en:mev-ad protocol'
(id=7141265 ; fe=en:mev-ad protocol ; type=1 ; niveau=200 ;
luminosité=25 ;
somme entrante=353 creation date=2017-06-25 touchdate=2025-05-10 11:36:20.000) ≈ 8 relations sortantes
- en:mev-ad protocol --
r_associated #0: 35 / 1 ->
en:cyclophosphamide
n1=en:mev-ad protocol | n2=en:cyclophosphamide | rel=r_associated | relid=0 | w=35
- en:mev-ad protocol --
r_associated #0: 35 / 1 ->
en:mev-a(d) protocol
n1=en:mev-ad protocol | n2=en:mev-a(d) protocol | rel=r_associated | relid=0 | w=35
- en:mev-ad protocol --
r_associated #0: 31 / 0.886 ->
en:methotrexate
n1=en:mev-ad protocol | n2=en:methotrexate | rel=r_associated | relid=0 | w=31
- en:mev-ad protocol --
r_associated #0: 28 / 0.8 ->
en:dexamethasone
n1=en:mev-ad protocol | n2=en:dexamethasone | rel=r_associated | relid=0 | w=28
- en:mev-ad protocol --
r_associated #0: 27 / 0.771 ->
en:vincristine
n1=en:mev-ad protocol | n2=en:vincristine | rel=r_associated | relid=0 | w=27
- en:mev-ad protocol --
r_associated #0: 26 / 0.743 ->
en:antineoplastic combined chemotherapy protocols
n1=en:mev-ad protocol | n2=en:antineoplastic combined chemotherapy protocols | rel=r_associated | relid=0 | w=26
- en:mev-ad protocol --
r_associated #0: 20 / 0.571 ->
cyclophosphamide
n1=en:mev-ad protocol | n2=cyclophosphamide | rel=r_associated | relid=0 | w=20
- en:mev-ad protocol --
r_associated #0: 2 / 0.057 ->
en:therapeutic or preventive procedure
n1=en:mev-ad protocol | n2=en:therapeutic or preventive procedure | rel=r_associated | relid=0 | w=2
| ≈ 16 relations entrantes
- cyclophosphamide ---
r_associated #0: 74 -->
en:mev-ad protocol
n1=cyclophosphamide | n2=en:mev-ad protocol | rel=r_associated | relid=0 | w=74
- en:cyclophosphamide ---
r_associated #0: 73 -->
en:mev-ad protocol
n1=en:cyclophosphamide | n2=en:mev-ad protocol | rel=r_associated | relid=0 | w=73
- en:mev-a(d) protocol ---
r_associated #0: 34 -->
en:mev-ad protocol
n1=en:mev-a(d) protocol | n2=en:mev-ad protocol | rel=r_associated | relid=0 | w=34
- en:antineoplastic combined chemotherapy protocols ---
r_associated #0: 30 -->
en:mev-ad protocol
n1=en:antineoplastic combined chemotherapy protocols | n2=en:mev-ad protocol | rel=r_associated | relid=0 | w=30
- en:dexamethasone ---
r_associated #0: 20 -->
en:mev-ad protocol
n1=en:dexamethasone | n2=en:mev-ad protocol | rel=r_associated | relid=0 | w=20
- en:methotrexate ---
r_associated #0: 20 -->
en:mev-ad protocol
n1=en:methotrexate | n2=en:mev-ad protocol | rel=r_associated | relid=0 | w=20
- en:vincristine ---
r_associated #0: 20 -->
en:mev-ad protocol
n1=en:vincristine | n2=en:mev-ad protocol | rel=r_associated | relid=0 | w=20
- cyclope (oeil) ---
r_associated #0: 15 -->
en:mev-ad protocol
n1=cyclope (oeil) | n2=en:mev-ad protocol | rel=r_associated | relid=0 | w=15
- Cyclophosphamide ---
r_associated #0: 10 -->
en:mev-ad protocol
n1=Cyclophosphamide | n2=en:mev-ad protocol | rel=r_associated | relid=0 | w=10
- dexaméthasone ---
r_associated #0: 10 -->
en:mev-ad protocol
n1=dexaméthasone | n2=en:mev-ad protocol | rel=r_associated | relid=0 | w=10
- en:cyclops eye ---
r_associated #0: 10 -->
en:mev-ad protocol
n1=en:cyclops eye | n2=en:mev-ad protocol | rel=r_associated | relid=0 | w=10
- méthotrexate ---
r_associated #0: 10 -->
en:mev-ad protocol
n1=méthotrexate | n2=en:mev-ad protocol | rel=r_associated | relid=0 | w=10
- vincristine ---
r_associated #0: 10 -->
en:mev-ad protocol
n1=vincristine | n2=en:mev-ad protocol | rel=r_associated | relid=0 | w=10
- cyclopeptide ---
r_associated #0: 5 -->
en:mev-ad protocol
n1=cyclopeptide | n2=en:mev-ad protocol | rel=r_associated | relid=0 | w=5
- cyclophiline ---
r_associated #0: 5 -->
en:mev-ad protocol
n1=cyclophiline | n2=en:mev-ad protocol | rel=r_associated | relid=0 | w=5
- cyclophorie ---
r_associated #0: 5 -->
en:mev-ad protocol
n1=cyclophorie | n2=en:mev-ad protocol | rel=r_associated | relid=0 | w=5
|